Lixin Guo

3.6k citations
110 papers · 1.5k indexed · 1 hit paper · h-index 21

Lixin Guo

98 papers receiving 1.5k citations

Hit Papers

The Antidepressant Effects of GLP-1 Receptor Agonists: A ...872023202620242025255075

Peers

Lixin Guo
Comparison fields: 5 of 121
  • Endocrinology, Diabetes and Metabolism 634
  • Genetics 237
  • Physiology 210
  • Industrial and Manufacturing Engineering 64
  • Molecular Biology 462
Replace Elizabeth Selvin with:
Elizabeth Selvin United States
Fàtima Sabench Spain
Yanyan Chen China
Jianyong Ma United States
Ricardo J. Bosch Spain
Kupper A. Wintergerst United States
Cai‐Mei Zheng Taiwan
Yugang Dong China
T. S. Danowski United States
Xuan Li China
Lixin Guo relative to Elizabeth Selvin United States Elizabeth Selvin's profile →
Citations per field
00.5×9.1×
Elizabeth Selvin · 1×
Citations per year

Countries citing papers authored by Lixin Guo

Since Specialization
Citations

This map shows the geographic impact of Lixin Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixin Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixin Guo more than expected).

Fields of papers citing papers by Lixin Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixin Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixin Guo. The network helps show where Lixin Guo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lixin Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lixin Guo Line = papers co-authored together Lixin Guo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20249
4 20240
5 20245
6 20240
7 20230
8 20237
9 20231
10 20228
11 20228
12 20214
13 202121
14 20205
15 20203
16 201924
17 201710
18 20163
19 201511
20
Diabetes and osteoporosis.
20091

About Lixin Guo

Lixin Guo is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Cardiology and Cardiovascular Medicine, having authored 110 papers that have together received 1.5k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (41 papers), Metabolism, Diabetes, and Cancer (29 papers), Diabetes Management and Research (21 papers), Pharmacology and Obesity Treatment (10 papers), Diabetes and associated disorders (7 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers), Thyroid Disorders and Treatments (6 papers) and Bone Metabolism and Diseases (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (634 citations), Genetics (237 citations) and Physiology (210 citations). Lixin Guo has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Qi Pan, Weihao Wang, Linong Ji, Xiaoxia Wang, Weiping Jia, Jianping Weng, Zhiguang Zhou, Yiming Mu, Dalong Zhu and Xiaoping Luo. Their work appears in journals such as Blood, The Journal of Clinical Endocrinology & Metabolism and Diabetes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026